Genethon-Product Pipeline Review-2015

Genethon-Product Pipeline Review-2015

  • Products Id :- GMDHC06787CDB
  • |
  • Pages: 34
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Genethon-Product Pipeline Review-2015


Global Markets Direct's, 'Genethon-Product Pipeline Review-2015', provides an overview of the Genethon's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Genethon's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


The report provides brief overview of Genethon including business description, key information and facts, and its locations and subsidiaries

The report reviews current pipeline of Genethon's human therapeutic division and enlists all their major and minor projects

The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones

Special feature on out-licensed and partnered product portfolio

The report summarizes all the dormant and discontinued pipeline projects

Latest company statement

Latest news and deals relating to the Genethon's pipeline products

Reasons To Buy

Evaluate Genethon's strategic position with total access to detailed information on its product pipeline

Assess the growth potential of Genethon in its therapy areas of focus

Identify new drug targets and therapeutic classes in the Genethon's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas

Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps

Develop strategic initiatives by understanding the focus areas of Genethon and exploit collaboration and partnership opportunities

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Plan mergers and acquisitions effectively by identifying the most promising pipeline of Genethon

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Explore the dormant and discontinued projects of Genethon and identify potential opportunities in those areas

Avoid Intellectual Property Rights related issues

Read More

Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications


Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Genethon Snapshot 5

Genethon Overview 5

Key Information 5

Key Facts 5

Genethon-Research and Development Overview 6

Key Therapeutic Areas 6

Genethon-Pipeline Review 8

Pipeline Products by Stage of Development 8

Pipeline Products-Monotherapy 9

Pipeline Products-Partnered Products 10

Partnered Products/Combination Treatment Modalities 11

Genethon-Pipeline Products Glance 12

Genethon-Clinical Stage Pipeline Products 12

Phase I Products/Combination Treatment Modalities 12

Genethon-Early Stage Pipeline Products 13

Preclinical Products/Combination Treatment Modalities 13

Genethon-Drug Profiles 14

G-1XCGD 14

Product Description 14

Mechanism of Action 14

R&D Progress 14

Gene Therapy to Activate WASP for Wiskott-Aldrich Syndrome 15

Product Description 15

Mechanism of Action 15

R&D Progress 15

Gene Therapy for Duchenne Muscular Dystrophy 17

Product Description 17

Mechanism of Action 17

R&D Progress 17

Gene Therapy to Activate Artemis for Radiosensitive Severe Combined Immunodeficiency 18

Product Description 18

Mechanism of Action 18

R&D Progress 18

Gene Therapy to Activate CNTF for Huntington's Disease 19

Product Description 19

Mechanism of Action 19

R&D Progress 19

Gene Therapy to Activate Dysferlin for Dysferlinopathies 20

Product Description 20

Mechanism of Action 20

R&D Progress 20

Gene Therapy to Activate FANC-A for Fanconi Anemia 21

Product Description 21

Mechanism of Action 21

R&D Progress 21

Gene Therapy to Activate Gamma-Sarcoglycan for Gamma-sarcoglycanopathy 22

Product Description 22

Mechanism of Action 22

R&D Progress 22

Gene Therapy to Activate SGCA for Alpha-sarcoglycanopathy 23

Product Description 23

Mechanism of Action 23

R&D Progress 23

Gene Therapy to Activate SMN1 for Spinal Muscular Atrophy 24

Product Description 24

Mechanism of Action 24

R&D Progress 24

Gene Therapy to Activate UGT1A1 for Crigler-Najjar Syndrome 25

Product Description 25

Mechanism of Action 25

R&D Progress 25

Genethon-Pipeline Analysis 26

Genethon-Pipeline Products by Target 26

Genethon-Pipeline Products by Route of Administration 27

Genethon-Pipeline Products by Molecule Type 28

Genethon-Pipeline Products by Mechanism of Action 29

Genethon-Recent Pipeline Updates 30

Genethon-Dormant Projects 31

Genethon-Locations And Subsidiaries 32

Head Office 32

Appendix 33

Methodology 33

Coverage 33

Secondary Research 33

Primary Research 33

Expert Panel Validation 33

Contact Us 33

Disclaimer 34

List of Tables

Genethon, Key Information 5

Genethon, Key Facts 5

Genethon-Pipeline by Indication, 2015 7

Genethon-Pipeline by Stage of Development, 2015 8

Genethon-Monotherapy Products in Pipeline, 2015 9

Genethon-Partnered Products in Pipeline, 2015 10

Genethon-Partnered Products/ Combination Treatment Modalities, 2015 11

Genethon-Phase I, 2015 12

Genethon-Preclinical, 2015 13

Genethon-Pipeline by Target, 2015 26

Genethon-Pipeline by Route of Administration, 2015 27

Genethon-Pipeline by Molecule Type, 2015 28

Genethon-Pipeline Products by Mechanism of Action, 2015 29

Genethon-Recent Pipeline Updates, 2015 30

Genethon-Dormant Developmental Projects,2015 31

List of Figures

Genethon-Pipeline by Top 10 Indication, 2015 7

Genethon-Pipeline by Stage of Development, 2015 8

Genethon-Monotherapy Products in Pipeline, 2015 9

Genethon-Partnered Products in Pipeline, 2015 10

Genethon-Pipeline by Top 10 Target, 2015 26

Genethon-Pipeline by Top 10 Route of Administration, 2015 27

Genethon-Pipeline by Top 10 Molecule Type, 2015 28

Genethon-Pipeline Products by Top 10 Mechanism of Action, 2015 29

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@]

Current R&D Portfolio of Genethon; Genethon - Key Therapeutics; Genethon - Pipeline Overview and Promising Molecules; Genethon - News; Genethon - Latest Updates; Genethon - Pipeline; Genethon - Discontinued/Dormant Projects

select a license

Single User License
USD 1500 INR 101175
Site License
USD 3000 INR 202350
Corporate User License
USD 4500 INR 303525



Coherent, high-quality, thoroughly-researched reports. We received a very quick response to all our queries which eventually expedited the entire process....

Well structured, the insights they shared with us were very helpful and reliable. Their timely assistance make their services invaluable to us. I would highly recommend them and would definitely use them again in the future if needed...

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies....

Related Products in vertical
Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India


Company Brochure

Engage with Us

sales [@]